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Abstract
AIM: To assess the impact of percutaneous cardiac 
support in cardiogenic shock (CS) complicating acute 
myocardial infarction (AMI), treated with percutaneous 
coronary intervention. 
METHODS: We selected all of the studies published 
from January 1st, 1997 to May 15st, 2015 that compared 
the following percutaneous mechanical support in 
patients with CS due to AMI undergoing myocardial 
revascularization: (1) intra-aortic balloon pump (IABP) vs  
Medical therapy; (2) percutaneous left ventricular assist 
devices (PLVADs) vs  IABP; (3) complete extracorporeal 
life support with extracorporeal membrane oxygenation 
(ECMO) plus IABP vs  IABP alone; and (4) ECMO plus 
IABP vs  ECMO alone, in patients with AMI and CS 
undergoing myocardial revascularization. We evaluated 
the impact of the support devices on primary and secon-
dary endpoints. Primary endpoint was the inhospital 
mortality due to any cause during the same hospital 
stay and secondary endpoint late mortality at 6-12 mo 
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of follow-up. 
RESULTS: One thousand two hundred and seventy-
two studies met the initial screening criteria. After 
detailed review, only 30 were selected. There were 
6 eligible randomized controlled trials and 24 eligible 
observational studies totaling 15799 patients. We found 
that the inhospital mortality was: (1) significantly higher 
with IABP support vs  medical therapy (RR = +15%, P  
= 0.0002); (2) was higher, although not significantly, 
with PLVADs compared to IABP (RR = +14%, P = 0.21); 
and (3) significantly lower in patients treated with 
ECMO plus IABP vs  IABP (RR = -44%, P = 0.0008) or 
ECMO (RR = -20%, P = 0.006) alone. In addition, Trial 
Sequential Analysis showed that in the comparison of 
IABP vs  medical therapy, the sample size was adequate 
to demonstrate a significant increase in risk due to IABP. 
CONCLUSION: Inhospital mortality was significantly 
higher with IABP vs  medical therapy. PLVADs did not 
reduce early mortality. ECMO plus IABP significantly 
reduced inhospital mortality compared to IABP. 
Key words: Intra-aortic balloon pump; Impella; Tan-
demHeart; Extracorporeal membrane oxygenation; 
Cardiogenic shock; Meta-analysis
© The Author(s) 2016. Published by Baishideng Publishing 
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Core tip: Meta-analyses from observational studies 
represent an area of innovation in statistical science. 
In the present review, we identified only a small 
number of randomized trials, which by themselves were 
underpowered to assess the efficacy of the support 
devices on inhospital mortality. To increase the power 
of the analysis we included observational data, which 
enabled us to add 14909 additional patients to the 890 
from the randomized controlled trials selected. The 
results of the analysis showed that: (1) intra-aortic 
balloon pump (IABP) used alone was associated with 
significant increase in inhospital mortality compared 
to Medical therapy; (2) percutaneous left ventricular 
assist devices increased, although non significantly, the 
mortality as compared with IABP; and (3) extracorporeal 
membrane oxygenation (ECMO) plus IABP had signi-
ficant protective effect compared to IABP or ECMO 
alone. 
Romeo F, Acconcia MC, Sergi D, Romeo A, Francioni S, 
Chiarotti F, Caretta Q. Percutaneous assist devices in acute 
myocardial infarction with cardiogenic shock: Review, meta-
analysis. World J Cardiol 2016; 8(1): 98-111  Available from: 
URL: http://www.wjgnet.com/1949-8462/full/v8/i1/98.htm  DOI: 
http://dx.doi.org/10.4330/wjc.v8.i1.98
INTRODUCTION
Cardiogenic shock (CS) occurs in 5% to 15% of 
patients with acute myocardial infarction (AMI). Despite 
major technical advances the inhospital mortality 
of these patients continues to remain unacceptably 
high at over 40%[1-4]. To date immediate myocardial 
revascularization represents the only intervention of 
proven benefit. Emergency percutaneous coronary 
intervention (PCI) is recommended if coronary anatomy 
is amenable and emergency surgical revascularization 
is recommended in case coronary anatomy is not 
amenable for PCI (AHA/ACC and ESC/EACTS indication: 
Class I, Level B)[5-7]. In order to maintain hemodynamic 
stabilization before and/or after early revascularization, 
mechanical support with devices such as intra-aortic 
balloon pump (IABP), percutaneous left ventricular 
assist devices (PLVADs) and complete extracorporeal 
life support with extracorporeal membrane oxygenation 
(ECMO) are often considered[8]. It is known that IABP 
support provides significant benefit when used in 
association with thrombolysis; however, it is of no 
benefit when used in association with PCI[4,9,10].
It is of note that current guidelines do not recom-
mend routine use of IABP in AMI patients with CS 
complicating AMI (AHA/ACC and ESC/EACTS indication: 
Class III, Level A), but IABP use may be considered in 
these patients when CS is secondary to mechanical 
complications (AHA/ACC indication: Class IIa, Level 
C). Further, it is recommended that the use of PLVADs 
should be restricted for short-term circulatory support 
(AHA/ACC and ESC/EACTS indication: Class IIb, Level 
C)[5-7].
Because the sickest patients are often excluded from 
randomized controlled trials (RCTs), only few RCTs of 
circulatory assist devices have been conducted thus far. 
On the other hand, there are some data from clinical 
observational studies[11-15]. 
We present here a meta-analysis of available data, 
based on RCTs and observational studies, on the use of 
support devices in AMI patients with CS undergoing PCI 
with regard to inhospital and late mortality.
MATERIALS AND METHODS
Study definition (search and data extraction)
We performed a systematic PubMed and the Cochrane 
Library literature search using the terms relating to the 
intervention of interest “IABP” or “IABC”, “Impella”, 
“Tandemheart”, “PLVADs” “ECMO” or “extracorporeal 
life support” or “ECLS” or “CPS” in the setting of 
CS in patients with AMI undergoing percutaneous 
coronary revascularization. We performed additional 
manual literature search through: (1) the reference 
lists of retrieved articles and published reviews; and 
(2) the abstracts presented at recent (last five years) 
International Conferences.
Two investigators independently examined the 
designs, patient populations and interventions used, 
aiming to include only studies designed to test the effect 
of the percutaneous support in patients with CS due to 
AMI and undergoing myocardial revascularization. The 
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search was restricted to English-language journals and 
excluded studies on non-human subjects as well as 
articles unrelated to the topic. 
The study selection process is outlined in Figure 
1. The exclusion criteria were data from registries or 
studies with lack of a control group, the absence of 
mortality data, the presence of different timing for the 
outcome or, more generally, insufficient data for risk 
estimation. Disagreements were resolved by asking 
the opinion of a third reviewer to reach consensus at 
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each stage of the screening process. We selected all of 
the studies published from January 1st, 1997 to May 
15st, 2015 that compared the following percutaneous 
mechanical support in patients with CS due to AMI 
undergoing myocardial revascularization: (1) IABP vs 
Medical therapy; (2) PLVADs vs IABP; and (3) ECMO 
plus IABP vs IABP or ECMO. CS was defined by: (1) a 
decrease in systolic blood pressure to ≤ 90 mmHg for 
more than 30 min, in the absence of hypovolemia, or 
requiring vasopressor support; (2) a reduction of cardiac 
Records identified through 
PubMed searching
(n  = 1246)
Through the Cochrane Library and 
additional manual search 
(n  = 26)
Records identified for screening
(n  = 1272)
After duplicates removed
(n  = 1267)
Full-text articles assessed
for eligibility
(n  = 1076)
Selected articles
(n  = 33)
Studies included in 
quantitative synthesis
(n  = 30)
Records excluded (n  = 191)
Non-English                                        146
Non-Human                                          45
Full-text articles excluded (n  = 1043)
Age less than 19 yr                             266
Case reports                                       358
Reviews/meta-analysis                         153
Letters or comments                            110
Do not satisfy inclusion criteria              156
Comparison
IABP vs  medical therapy
PLVADs vs  IABP
ECMO + IABP vs  IABP
ECMO + IABP vs  ECMO
Total
IABP vs  medical therapy
Overall
Inhospital mortality
No. of
studies
Experimental 
group
Control 
group
Total
Events    Total     Events     Total
13       2016      4360     1783      4431      8791
6           66        118         73        153       271
3           32          88         46          76       164
6         116        196         72        105       301
28       2230       4762     1974      4765      9527
Late mortality
6       1816     3491      1396      3550      7041
30       3851     7865      3167      7934    15799
Figure 1  Flow-chart of the study selection process. IABP: Intra-aortic balloon pump; PLVADs: Percutaneous left ventricular assist devices; ECMO: Extracorporeal 
membrane oxygenation.
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done using the effective difference in risks between 
the experimental (intervention risk) and control groups 
(basal risk) with a risk of a type I error of 5% and 
a power of 80%. The relative risk reductions (RRR) 
observed were linked to the number of patients to be 
treated (NNT) or to be harmed (NNH), to assess the 
clinical benefit or the detrimental effect corresponding 
to each level of RRR. All statistical tests were two-
sided and α error of ≤ 0.05 was defined as statistically 
significant. 
The statistical methods of this study were reviewed 
by Flavia Chiarotti, Biostatistician, Research Director 
from the Italian National Institute of Health.
RESULTS
One thousand two hundred and seventy-two records 
met the initial screening criteria. After detailed review, 
only 30 were selected[4,18,21,27-54]. There were 6 eligible 
RCTs[4,27-31] and 24 eligible observational studies[18,21,32-54] 
totaling 15799 patients. The main characteristics of the 
selected studies are reported in Table 1.
IABP vs medical therapy 
In the comparison between IABP and Medical therapy, 
we analysed a total of 15063 patients (14273 from 12 
observational studies[32-44] and 790 form 3 RCTs[4,27,31]). 
The data provided us by French et al[31] and Kunadian et 
al[44] contributed only for the analysis of the secondary 
outcome.
Primary endpoint: Primary endpoint was assessed in 
8791 patients (8153 from 11 observational studies[32-43] 
and 638 from 2 RCTs[4,27]). The inhospital deaths 
occurred in 46.24% of patients in the experimental 
group and 40.24% of patients in the control. The NNH 
was 16 (6 more deaths every 100 patients treated 
with IABP). The overall analysis showed a significant 
risk increase (+18%, P = 0.002) in the IABP group 
(Figure 2). More specifically, we observed a significant 
risk increase in observational studies (RR = +21%, 
P = 0.0008) and a nonsignificant risk reduction in 
RCTs (RR = -3%%, P = 0.78) (Figure 2). The test 
for subgroup differences showed high heterogeneity 
among observational studies (I2 = 63%) and between 
observational and RCTs (I2 = 73.9%), providing a 
significantly different estimate of the IABP effect (Figure 
2). In the Funnel plot, the studies by Gu et al[37] and by 
Zeymer et al[39] fell out of the 95%CI, thus appearing 
to be the potential source of bias. After the sensitivity 
analysis, heterogeneity decreased to a lower level 
among the observational (I2 = 19%), but persisted at 
high levels between observational studies and RCTs 
(I2 = 68.2%) (Table 2). Furthermore the overall risk in 
the experimental group slight decreased (RR = +15%) 
(Table 2). The NNH was equal to 18 (5 more deaths 
every 100 patients treated with IABP) (Table 3). Trial 
Sequential Analysis showed that the required number of 
participant was reached and the monitoring boundaries, 
index to 1.8 L/min per square meter without support 
or to 2.0-2.2 L/min per square meter with support; 
and (3) elevated left ventricular filling pressures[16,17]. 
Moreover, profound shock was defined as systolic blood 
pressure less than 75 mmHg-despite receiving an 
intravenous inotropic agent that was associated with 
altered mental status and respiratory failure[18]. The 
acronym PLVADs included the Impella®2.5 (Abiomed, 
Danvers, MA, United States) and the TandemHeart 
(Cardiac Assist Inc., Pittsburgh, PA, United States)[14,15]. 
The acronym of ECMO included a modified heart-lung 
machine, generally consisted of a centrifugal pump, a 
heat exchanger and a membrane oxygenator[15,18-22].
Study outcomes
Primary and secondary endpoints: We evaluated 
the impact of the support devices on primary and 
secondary endpoints. Primary endpoint was the 
inhospital mortality due to any cause during the same 
hospital stay and secondary endpoint late mortality at 
6-12 mo of follow-up. 
Statistical analysis
Meta-analysis was performed separately for obser-
vational studies and RCTs comparing the following 
groups of patients: (1) IABP (experimental) vs Medical 
therapy (control); (2) PLVADs (experimental) vs IABP 
(control); (3) ECMO plus IABP (experimental) vs IABP 
(control); and (4) ECMO plus IABP (experimental) vs 
ECMO (control). We computed the risk ratio (RR) with 
95%CI, using the Mantel-Haenszel random-effect model 
to take into account possible heterogeneity among the 
individual studies beyond that expected from chance, 
to point out the relative effect of the mechanical assist 
devices under study. We used the Forest plot to present 
the results graphically, to report the effect estimates for 
the individual studies together with the overall measure 
of effect. We computed the Cochran’s Q test and I2 
statistics to quantify the homogeneity/heterogeneity 
among the selected studies within and between 
subgroups[23]. A Funnel Plot was designed as visual aid 
for detecting bias or systematic heterogeneity among 
the studies included in the meta-analysis (publication 
bias). A sensitivity analysis was then performed by 
repeating the meta-analysis after exclusion of the 
study(ies) falling out the 95%CI. 
The meta-analysis was performed using Review 
Manager (RevMan) (Computer program) Version 
5.3. Copenhagen: The Nordic Cochrane Centre, the 
Cochrane Collaborations, 2014[24]. 
We performed Trial Sequential Analysis using the 
program provide by “The Copenhagen Trial Unit, Center 
for Clinical Intervention Research CTU, Denmark; 
version 0.9 beta; available at www.ctu.dk/tsa” in order 
to assess if the studies enclosed in the meta-analysis 
reached the required number of participants (information 
size), and to construct the monitoring boundaries 
to detect significance and futility of the primary and 
secondary endpoints[25,26]. Trial Sequential Analysis was 
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  Ref. Setting Study design Etiology of CS Cardiac 
arrest
Treatment Period No. of 
pts
  IABP vs medical therapy
     Anderson et al[32], 1997 (GUSTO-I) United States, 
Europe 
Obs.; multicenter STEMI No PCI 1990-1993  37
     Sanborn et al[33], 2000 
     (SHOCK Registry) 
United States, 
Canada, 
Europe, New 
Zealand 
Obs.; multicenter registry AMI No  PCI or CABG 1993-1997 383
     Barron et al[34], 2001 (NRMI-2) United States Obs.; multicenter registry AMI No PCI 1994- < 2000   2990
     French et al[31], 2003 
     (SHOCK Trial 12-mo survival) 
United States, 
Canada, 
Europe, New 
Zealand 
RCT; multicenter AMI No PCI or CABG 1993-1998 152
     Vis et al[35,36], 2007 (AMC CS) Europe Obs.; single-center STEMI No PCI 1997-2005 292
     Gu et al[37], 2010 Asia Obs.; single-center  STEMI No  PCI 2003-2008   91
     Prondzinsky et al[27], 2010 
     (IABP-SHOCK) 
Europe RCT; single-center AMI No PCI 2003-2004   40
     Stub et al[38], 2011 Europe Obs.; multicenter registry  ACS No  PCI 2004-2010 410  
     Zeymer et al[39], 2011 
     (Euro Heart Survey PCI)
Europe Obs.; multicenter registry STEMI or 
NSTEMI 
No  PCI 2005-2008 653
     Thiele et al[4], 2012 
     (IABP-SCHOCK II) 
Europe RCT; multicenter AMI No  PCI (95.8%), CABG (3.5%), 
PCI and CABG (0.7%)
2009-2012 598
      Zeymer et al[40], 2013 
     (ALKK-PCI) 
Europe Obs.; multicenter registry STEMI or 
NSTEMI
No PCI 2006-2011   1913
     Dziewierz et al[41], 2014   
     (EUROTRANSFER registry) 
Europe Obs.; multicenter registry STEMI No PCI (49 pts), CABG (2 
pts)
2005-2007   51
     Kunadian et al[44], 2015 
     (BCIS registry) 
Europe Obs.; multicenter registry ACS No PCI 2005-2011   6120
     Kim et al[42], 2015 (KAMIR) Asia Obs.; multicenter registry AMI Yes PCI 2005-2014    1214
     Suzuki et al[43], 2015 (Tokyo 
     CCU Network Scientific Council)
Asia Obs.; multicenter registry STEMI No PCI 2009-2011 119
  PLVADs (TandemHeart, Impella® 2.5) vs IABP 
     Thiele et al[29], 20051 Europe RCT; single center AMI No PCI (49 pts), CABG (2 
pts)
2000-2003  41
     Burkoff et al[28], 20061 United States, 
Europe
RCT; multicenter AMI (70%) No PCI (22 pts), CABG (3 
pts)
2002-2004  33
     Seyfarth et al[30], 20082 
     (ISAR-SHOCK) 
Europe RCT; two-center AMI No PCI (22 pts) 2004-2007  26
     Schwartz et al[46], 20121,2 United States Obs.; single center 68% STEMI, 
11% OHCA
Yes PCI (63 pts), CABG (5 
pts)
2008-2010  76
     Shah et al[47], 20121,2 United States Obs.; single center STEMI or 
UA/NSTEMI
No PCI 2007-2009  17
     Manzo-Silberman et al[45], 20132 Europe Obs.; single center 
registry
ACS (mainly), 
OHCA 
Yes PCI (54 pts) 2007-2010   78
  ECMO plus IABP vs IABP
     Sheu et al[18], 2010 Asia Obs.; single center STEMI No PCI 1993-2009   71
     Tsao et al[21], 2012 Asia Obs.; single center  AMI No PCI 2004-2009   58
     Perazzolo Marra et al[48], 2013 Europe Obs.; single center AMI No PCI 2010-2012   35
  ECMO plus IABP vs ECMO
     Yamauchi et al[49], 2009 Asia Obs.; single center AMI No PCI 2000-2007   16
     Chung et al[50], 2011 Asia Obs.; multicenter AMI, INCA 
(14 pts)
Yes PCI (7 pts), CABG 
(13 pts)
2206-2009   20
     Kagawa et al[51], 2012 Asia Obs.; multicenter ACS, INCA, 
OHCA
Yes PCI 2004-2011   73
     Aoyama et al[52], 2014 Asia Obs.; single center AMI, INCA (2 
pts, OHCA 7 
pts)
Yes PCI (34 pts), CABG (4 
pts)
1993-2000   38
     Park et al[53], 2014 Asia Obs.; single center AMI No PCI (78 pts), PCI e/o 
CABG (10 pts), medical 
treatment (8 pts) 
2004-2011   96 
     Kim et al[54], 2014 Asia Obs.; multicenter ACS No PCI (53 pts), CABG (5 
pts)
2010-2013   58
Table 1  Main characteristics of the selected studies 
ACS: Acute coronary syndrome; AMI: Acute myocardial infarction; CABG: Coronary artery bypass grafting; CS: Cardiogenic shock; ECMO: Extracorporeal 
membrane oxygenation; IABP: Intra-aortic balloon pump; INCA: In-of-hospital cardiac arrest; NSTEMI: Non-ST-elevation myocardial infarction; PCI: Percutaneous 
coronary intervention; PLVADs: Percutaneous left ventricular assist devices with (1TandemHeart, or 2Impella® 2.5); pts: Patients; Obs.: Observational study; OHCA: 
Out-of-hospital cardiac arrest; RCT: Randomized controlled trial; STEMI: ST-elevation myocardial infarction; UA: Unstable angina.
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respect to control (52.02% vs 39.32%). IABP reduced 
mortality (-8%, P = 0.78) in observational studies and 
increased mortality (+16%, P = 0.34) in RCTs (Figure 
4). In the Funnel plot the studies by Gu et al[37] and by 
Thiele et al[56] fell out of the 95%CI, appearing to be the 
potential source of bias. When we applied the sensitivity 
analysis by excluding the study by Gu et al[37] from 
observational studies and the study by Thiele et al[56] 
constructed to detect significance, were crossed by the 
z-curves, demonstrating a detrimental effect of IABP 
(Table 3, Figure 3).
Secondary endpoint: The late mortality was asse-
ssed in 7041 patients (6262 from 3 observational 
studies[37,41,44] and 779 from 3 RCTs[4,27,31,55,56]). Mortality 
rate was higher, but not significantly, in the IABP group 
  Comparison/subgroup RR
Before After
n I 2 (%) Estimate 
(95%CI)
P n I 2 (%) Estimate (95%CI) P
  Inhospital mortality
     IABP vs medical therapy
        Observational studies 11 63 1.21 (1.08, 1.36)       0.0008   9 19 1.17 (1.09, 1.26)     < 0.0001
        RCTs   2   0 0.97 (0.81, 1.18)   0.78   2   0 0.97 (0.81, 1.18)        0.78
        Overall effect 13 62 1.18 (1.06, 1.32)     0.002 11 24 1.15 (1.07, 1.24)        0.0002
        Test for subgroup differences1 c 2 = 3.83, df = 1 (P = 0.05), I2 = 73.9% c 2 = 3.14, df = 1 (P = 0.08), I2 = 68.2%
     ECMO plus IABP vs ECMO
        Observational studies   6 12 0.78 (0.65, 0.94)     0.008   5   0 0.80 (0.68, 0.94)        0.006
  Late mortality
     IABP vs medical therapy
        Observational studies   3 90 0.92 (0.51, 1.67)   0.78   2 60 1.16 (0.69, 1.95)        0.57
        RCTs   3 32 1.16 (0.86, 1.58)   0.34   2   0 1.56 (0.97, 2.52)        0.07
        Overall effect   6 85 1.08 (0.82, 1.41)   0.60   4   0 1.38 (1.30, 1.46)     < 0.00001
        Test for subgroup differences1 c 2 = 0.48, df = 1 (P = 0.49), I2 = 0% c 2 = 0.68, df = 1 (P = 0.41), I2 = 0%
Table 2  Meta-analysis before and after sensitivity analysis
1Between observational studies and RCTs. IABP: Intra-aortic balloon pump; RCT: Randomized controlled trial; ECMO: Extracorporeal membrane 
oxygenation.
Subgroup/study
IABP               Control                                 Risk ratio                                Risk ratio
Events   Total    Events    Total   Weight         M-H, Random, 95%CI          M-H, Random, 95%CI
Observational studies
Anderson, 1997 (GUSTO-I)
Sanborn, 2000 (SHOCK Registry)
Barron, 2001 (NRMI-2)
Vis, 2007 (AMC CS)
Gu, 2010
Stub, 2011
Zeymer, 2011 (EHS-PCI Registry)
Zeymer, 2013 (ALKK-PCI Registry)
Dziewierz, 2014 (EUROTRANSFER Registry)
Kim, 2015 (KAMIR)
Suzuki, 2015
Subtotal (95%CI)
Total events
Heterogeneity: Tau2 = 0.02, c 2 = 27.18, df = 10 (P  = 0.002); I 2 = 63%
Test for overall effect: Z  = 3.36 (P  = 0.0008)
RCTs
Prondinsky, 2010 (IABP-SHOCKⅠ)
Thiele, 2012 (IABP-SHOCK Ⅱ)
Subtotal (95%CI)
Total events
Heterogeneity: Tau2 = 0.00, c 2 = 0.39, df = 1 (P  = 0.53); I 2 = 0%
Test for overall effect: Z  = 0.27 (P  = 0.78)
Total (95%CI)
Total events
Heterogeneity: Tau2 = 0.02, c 2 = 31.29, df = 12 (P  = 0.002); I 2 = 62%
Test for overall effect: Z  = 3.12 (P  = 0.002)
Test for subgroup differences: c 2 = 3.83, df = 1 (P  = 0.05), I 2 = 73.9%
13
120
956
93
13
108
92
212
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242
31 
1890
7
119
126
2016
21
304
2035
199
43
251
162
487
30
425
84
4041
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4360
7
30
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26
25
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177
534
8
387
5
1654
6
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129
1783
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491
1426
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789
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4112
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298
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4431
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1.4%
87.5%
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Figure 2  Meta-analysis on risk ratio of inhospital mortality between the patients with intra-aortic balloon pump vs medical therapy.
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PLVADs vs IABP 
We compared the effect of PLVADs vs IABP in 271 
patients; 171 from 3 observational studies[45-47] and 100 
from 3 RCTs[28-30]. 
Primary endpoint: The overall inhospital mortality 
increased although not significantly, in PLVADs group 
compared to IABP group, both in the observational 
studies (+16%, P = 0.20) and the RCTs (+6%, P = 
0.80) (Figure 5). The test for subgroup differences did 
not show significant differences between observational 
studies and RCTs (c 2 = 0.13, P = 0.72, I2 = 0%). 
Indeed, in the Forest plot the confidence intervals 
overlapped, P values of the c2 tests were all greater than 
0.10 and the I2 statistics were all equal to zero, showing 
the homogeneity among the studies within both 
from RCTs, the overall I2 decreased from 85% to 0% 
(Table 2). Moreover, the test for subgroup differences 
showed that the heterogeneity between observational 
and RCTs was lower (I2 = 0%) and an overall significant 
detrimental effect of IABP was found (Table 2). Trial 
Sequential Analysis was performed: (1) by including all 
studies; and (2) by excluding the study by Gu et al[37] 
and that by Thiele et al[56] according to the sensitivity 
analysis (Table 3). With inclusion of all studies, there 
was a 32.28% mortality increase in the IABP group 
with about 13 more deaths every 100 treated patients. 
When studies by Gu et al[37] and Thiele et al[56] were 
excluded, IABP support resulted in a 38.22% risk 
increase, and Trial Sequential Analysis showed that data 
were sufficient to highlight the harmful effect of IABP 
support on the late mortality (Table 3). 
  Groups Mortality rate (%) RRR Effect of experimental support Trial Sequential Analysis
  Experimental Control Experimental Control NNT NNH Harm1 Benefit1 Required information 
size
Results
  Inhospital mortality 
     IABP2 vs Medical 
therapy2
45.99 40.62   -13.22 18     5.37 2174 Conclusive 
     PLVADs vs IABP 55.93 47.71   -17.23 12     8.22 1161 Inconclusive 
     ECMO + IABP vs IABP 36.36 60.53   39.92   5 24.16   150 Conclusive 
     ECMO + IABP2 vs ECMO2 61.29 66.67     8.06 19    5.38 Not calculable Inconclusive
  Late mortality
     IABP vs Medical 
therapy
52.02 39.32   -32.28   7   12.70 5984 Futility
     IABP2 vs Medical 
therapy2
52.08 37.68   -38.22   6   14.40   168 Conclusive 
Table 3  Benefit - harm observed in the experimental group and result of Trial Sequential Analysis 
1Number of patients out of 100; 2Comparison after sensitivity analysis.
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Figure 3  Intra-aortic balloon pump vs medical therapy: Trial Sequential Analysis on inhospital mortality. IABP: Intra-aortic balloon pump.
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studies[49-54]. We did not find any RCTs that analyzed this 
topic. We found a significantly lower inhospital mortality 
(RR = -22%, P = 0.008) in the group of patients 
treated with ECMO plus IABP compared to ECMO alone 
(Figure 6). In the Funnels plot analysis, only the study 
by Yamauchi et al[49] could be a potential source of 
bias. After the sensitivity analysis I2 decreased to 0% 
while the significant effect of ECMO plus IABP vs ECMO 
remained substantially unchanged (RR = -20%, P = 
0.006) (Table 2). Despite these results, Trial Sequential 
Analysis could not be performed because of the small 
number of patients included (Table 3). 
DISCUSSION
All recent reviews on the use of support devices in AMI 
patient with CS undergoing PCI thus far show lack of 
a meta-analytic estimates[11-15], probably because the 
results were based mainly on registry data. 
Meta-analyses of data from observational studies 
represent an area of innovation in statistical science. 
This analysis can be performed when the question of 
interest cannot be answered by a review of randomized 
controlled trials. Even though observational studies 
are prone to bias (including confounding variables), 
strategies to adjust for unmeasured confounding 
variables can be adopted[23]. In the present review, we 
identified only a small number of randomized trials, 
which by themselves were underpowered to assess the 
efficacy of the support devices on inhospital mortality. 
To increase the power of the analysis we included 
observational data, which enabled us to add 14909 
additional patients to the 890 from the RCTs selected. 
Further, to avoid bias we used the Funnel plot analysis, 
observational and RCTs (Figure 5). In the Funnel plot, 
all studies were enclosed into 95%CI and the larger 
studies were plotted at the central top of the graph, 
demonstrating a convergence in risk estimation while 
increasing the sample size. RRR equaled -17.23%; when 
translated into clinical terms, use of PLVADs resulted 8 
more deaths every 100 patients treated. For appropriate 
Trial Sequential Analysis, more patients would have to 
be included (Table 3).
ECMO plus IABP vs IABP 
Primary endpoint: We compared the effect of ECMO 
plus IABP vs IABP in 164 patients from 3 observational 
studies[18,21,48]. We did not find any RCTs on the topic. In 
the Forest plot the c2 test and the I2 statistics detected 
the absence of significant heterogeneity (I2 = 7%). 
In the Funnel plot analysis, all studies within 95%CI 
were included. The inhospital mortality was higher 
when IABP was used alone rather than in combination 
with ECMO (60.53% vs 36.36%, respectively). ECMO 
plus IABP group showed a 44% reduction in mortality 
(Figure 6). The observed RRR was 39.92%, which 
means that there were 24 fewer deaths for every 100 
treated patients. Trial Sequential Analysis showed that 
the cumulative Z-curve crossed the alpha-spending 
boundaries, demonstrating that a significant RRR was 
obtained when ECMO support was used in association 
with IABP (Figure 7). The required numbers of patients 
was reached and the meta-analysis could be considered 
conclusive (Table 3, Figure 7).
ECMO plus IABP vs ECMO
Primary endpoint: We compared the effect of ECMO 
plus IABP vs IABP in 301 patients from 6 observational 
Subgroup/study
IABP                Control                                  Risk ratio                                Risk ratio
Events   Total    Events    Total   Weight           M-H, Random, 95%CI             M-H, Random, 95%CI
Observational studies
Gu, 2010
Dziewierz, 2014
Kunadian, 2015 (BCIS Registry)
Subtotal (95%CI)
Total events
Heterogeneity: Tau2 = 0.23, c 2 = 20.01, df = 2 (P  < 0.0001); I 2 = 90%
Test for overall effect: Z  = 0.28 (P  = 0.78)
RCTs
French, 2003 (SHOCK Trial)
Prondinsky, 2010 (IABP-SHOCKⅠ)
Thiele, 2012 (IABP-SHOCK Ⅱ)
Subtotal (95%CI)
Total events
Heterogeneity: Tau2 = 0.03, c 2 = 2.93, df = 2 (P  = 0.23); I 2 = 32%
Test for overall effect: Z  = 0.96 (P  = 0.34)
Total (95%CI)
Total events
Heterogeneity: Tau2 = 0.07, c 2 = 32.56, df = 5 (P  < 0.00001); I 2 = 85%
Test for overall effect: Z  = 0.52 (P  = 0.60)
Test for subgroup differences: c 2 = 0.48, df = 1 (P  = 0.49), I 2 = 0%
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1.38 [1.31, 1.46]
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Figure 4  Meta-analysis on risk ratio of late mortality between the patients with intra-aortic balloon pump vs medical therapy.
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From the meta-analysis we can make the following 
conclusions
First, in the comparison between IABP vs Medical 
therapy, the analysis confirmed that IABP support 
the Cochran’s Q test and I2 statistics to test differences 
between groups and subgroups. The sensitivity analysis 
allowed us to make comparisons not affected by 
excessive heterogeneity.
Observational studies
Schwartz, 2012
Shah, 2012
Manzo-Silberman, 2013
Subtotal (95%CI)
Total events
Heterogeneity: Tau2 = 0.00, c 2 = 0.95, df = 2 (P  = 0.62); I 2 = 0%
Test for overall effect: Z  =1.27 (P  = 0.20)
RCTs
Thiele, 2005
Burkoff, 2006
Seyfarff, 2008 (ISAR-SHOCK)
Subtotal (95%CI)
Total events
Heterogeneity: Tau2 = 0.00, c 2 = 0.38, df = 2 (P  = 0.83); I 2 = 0%
Test for overall effect: Z  = 0.26 (P  = 0.80)
Total (95%CI)
Total events
Heterogeneity: Tau2 = 0.00, c 2 = 1.40, df = 5 (P  = 0.92); I 2 = 0%
Test for overall effect: Z  = 1.25 (P  = 0.21)
Test for subgroup differences: c 2 = 0.13, df = 1 (P  = 0.72), I 2 = 0%
PLVADs                IABP                                    Risk ratio                                    Risk ratio
Events    Total     Events    Total   Weight            M-H, Random, 95%CI                   M-H, Random, 95%CISubgroup/study
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Figure 5  Meta-analysis on risk ratio of inhospital mortality between the patients with percutaneous left ventricular assist devices vs intra-aortic balloon 
pump. IABP: Intra-aortic balloon pump; PLVADs: Percutaneous left ventricular assist devices.
ECMO plus IABP vs  IABP
Sheu, 2010
Tsao, 2012
Perazzolo Marra, 2013
Subtotal (95%CI)
Total events
Heterogeneity: Tau2 = 0.01, c 2 = 2.16, df = 2 (P  = 0.34); I 2 = 7%
Test for overall effect: Z  =3.35 (P  = 0.0008)
ECMO plus IABP vs  ECMO
Yamauchi, 2009
Chung, 2011
Kagawa, 2012 
Aoyama, 2014
Park, 2014
Kim, 2014
Subtotal (95%CI)
Total events
Heterogeneity: Tau2 = 0.01, c 2 = 5.68, df = 5 (P  = 0.34); I 2 = 12%
Test for overall effect: Z  = 2.67 (P  = 0.008)
ECMO + IABP            Control                                   Risk ratio                                      Risk ratio
Events    Total      Events      Total    Weight            M-H, Random, 95%CI                 M-H, Random, 95%CISubgroup/study
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0.54 [0.35, 0.84]
0.45 [0.25, 0.80]
1.00 [0.41, 2.46]
0.56 [0.40, 0.78] 
0.24 [0.08, 0.74]
1.00 [0.38, 2.60]
0.77 [0.61, 0.96]
0.94 [0.41, 2.18]
0.94 [0.64, 1.38]
1.74 [0.54, 1.01]
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Figure 6  Meta-analysis on risk ratio of inhospital mortality between the patients with extracorporeal membrane oxygenation plus Intra-aortic balloon pump 
vs intra-aortic balloon pump or extracorporeal membrane oxygenation alone. IABP: Intra-aortic balloon pump; ECMO: Extracorporeal membrane oxygenation.
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complete revascularization and improved survival in the 
setting of refractory CS complicating AMI.
In our analysis, the PLVADs increased, although 
non significantly, the mortality as compared with 
IABP. The Trial Sequential Analysis showed that 1161 
patients will need be analyzed in order to demonstrate 
its detrimental effect. Our meta-analysis was as such 
inconclusive and additional perspective investigations 
would be needed to definitive conclusion.
Third, relative to comparisons of ECMO plus IABP vs 
IABP or ECMO plus IABP vs ECMO, the meta-analysis 
showed a significant protective effect of ECMO plus IABP 
on inhospital mortality compared to IABP or ECMO used 
alone (Figure 6). Moreover, Trial Sequential Analysis 
showed that in the comparison ECMO plus IABP vs IABP 
the required numbers of patients was reached and the 
meta-analysis could be considered conclusive (Figure 7).
Potential limitation 
The main limitation of this meta-analysis is the inclusion 
of the observational studies, since they are viewed 
as having less validity than RCTs, due to the absence 
of randomization. Indeed, we cannot exclude that 
CS was more severe in the IABP group compared 
to Medical therapy in some observational studies 
included in our meta-analysis. However, we repeated 
the analysis, including only the observational studies, 
between IABP vs control group, selected according 
to the same severity of shock. The results were 
substantially unchanged (RR = 1.11, 95%CI = 1.02 
to 1.21), significantly in favour of Medical therapy. The 
heterogeneity was absent (I2 = 0%). If RCTs were 
was associated with a significant increase inhospital 
mortality (Figure 2). The results of RCTs were marginal 
probably because of the small sample size and the 
results could be considered a chance occurrence (Figures 
2 and 4). When we included the data from observational 
studies and applied the sensitivity analysis the results 
were affected only low heterogeneity (I2 = 19%). 
Trial Sequential Analysis showed that the Z-curves 
surpassed not only the conventional boundaries but 
also the alpha-spending boundaries, constructed to 
control for type 1 error as the source of bias. Thus, the 
meta-analysis can be considered conclusive in terms 
of showing a detrimental effect of IABP (Figure 3). 
With regard to late mortality, we did not identify any 
difference in both observational studies or in RCTs. 
However, after sensitivity analysis a significantly higher 
late mortality was observed in IABP-treated patients 
and was confirmed by Trial Sequential Analysis, that 
was conclusive (Table 3). 
Second, relative the comparison between IABP vs 
PLVADs, recently reported studies have failed to show a 
hemodynamic or survival benefit of mechanical support 
in AMI patients with CS and undergoing PCI. The 
meta-analysis by Cheng et al[57] dates back to 2009, 
performed on 3 RCTs and included 100 patients, showed 
that although PLVADs provided superior haemodynamic 
support in patients with CS compared to IABP, the use 
of these more powerful devices did not significantly 
improve early survival. Afterwards only observational 
studied were performed on this topic. O’Neill et al[58] 
suggested that early initiation of hemodynamic support 
prior to PCI with Impella 2.5 was associated with more 
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Figure 7  Extracorporeal membrane oxygenation plus Intra-aortic balloon pump support vs Intra-aortic balloon pump alone: Trial Sequential Analysis on 
inhospital mortality. IABP: Intra-aortic balloon pump; ECMO: Extracorporeal membrane oxygenation.
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Research frontiers 
The question of impact of cardiac support percutaneous devices cannot be 
answered by a review of RCTs alone. Meta-analyses of observational studies 
increase the power of the analysis by adding more data to the RCTs to have more 
comprehensive results.
 
Innovations and breakthroughs
In the present study, the authors investigated the impact of IABP, PLVADs and 
ECMO on inhospital mortality and late survival in patients with CS complicating 
acute myocardial infarction (AMI) undergoing percutaneous coronary intervention 
(PCI). Meta-analysis of observational studies in addition to the RCTs enabled 
them to increase the power of the analysis.
 
Applications
The results of the meta-analysis allow us to understand the impact of percu-
taneous cardiac support with IABP, PLVAD and ECMO in patients with CS 
complicating AMI undergoing PCI. 
 
Terminology
This is a systematic review and meta-analysis of observational studies and RCTs.
 
Peer-review
In this study, the authors collected the data from 30 published research papers 
(total 15799 patients) and used meta-analysis to analyze in hospital and late 
mortality of percutaneous mechanical support. This is an interesting study. The 
findings in this study have the potential to help the clinical doctor work out the 
guideline for reducing mortality in acute myocardial infarction complicated by 
cardiogenic shock.
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Conclusion
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mortality was significantly higher with IABP support vs 
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significantly, the mortality as compared with IABP; and 
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